Novel Therapy for Multiple Myeloma: Future Directions in Care
Looking toward the future management of patients with multiple myeloma, Rafael Fonseca, MD, shares excitement for novel therapeutic strategies.
2-Year Followup Data From the GRIFFIN Trial in Transplant-Ineligible NDMM
Updated results from the GRIFFIN trial in newly diagnosed multiple myeloma, including consideration for frontline 4-drug regimens and depth of response.
Multiple Myeloma: Current Approaches to Frontline Therapy
Taking into account data from the ASH 2021 annual meeting, Rafael Fonseca, MD, reviews his current approaches to frontline therapy for patients with multiple myeloma.
Rescue Isatuximab in Transplant-Ineligible, Treatment Naïve NDMM
Rafael Fonseca, MD, reviews data on rescue isatuximab from the ASH 2021 annual meeting and discusses use of best therapies up front.
Frontline Use of Daratumumab-Based Regimens in Transplant-Ineligible MM
Insight on the survival benefit seen with frontline daratumumab-based regimens in patients with transplant-ineligible multiple myeloma.
The MASTER Trial: Frontline Dara-KRd in Newly Diagnosed Multiple Myeloma
Expert perspective on results from the MASTER trial, which analyzed dara-KRd as frontline therapy with MRD-adapted use in newly diagnosed multiple myeloma.
Upcoming Post-Conference Perspectives: ASH 2021
Rafael Fonseca, MD, shares his excitement for an upcoming AJMC Post-Conferences Perspectives video series covering the 2021 American Society of Hematology annual meeting.
